Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07617870
PHASE3

Pro-urokinase for Extended-Window Posterior Circulation Stroke

Sponsor: The First Affiliated Hospital of Zhengzhou University

View on ClinicalTrials.gov

Summary

This study aims to evaluate whether, in patients with imaging-confirmed acute ischemic stroke of the posterior circulation presenting within 4.5-24 hours after symptom onset and not scheduled for endovascular thrombectomy, intravenous thrombolysis with recombinant human prourokinase (rhPro-UK), compared with standard medical treatment, can achieve superior 90-day functional outcomes with a higher level of safety.

Official title: Pro-urokinase for Reperfusion in Acute pOsterior Circulation ischeMIc Stroke in the Extended Window (the PROMISE Trail): A Randomized, Double-blind, Baseline Treatment-controlled Study

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

586

Start Date

2026-06-01

Completion Date

2028-06-30

Last Updated

2026-06-01

Healthy Volunteers

No

Interventions

DRUG

rhPro-UK

rhPro-UK (5 mg/vial), to maximum of 35mg

DRUG

placebo

Asprin (placebo)

DRUG

Aspirin

Asprin (300mg)

DRUG

Placebo

rhPro-UK(placebo)

Locations (1)

Department of Neurology, the First Affiliated Hospital of Zhengzhou University

Zhengzhou, Henan, China